Menu
Log in


Patent Information Users Group, Inc.

The International Society for Patent Information Professionals

Log in

USPTO Biotechnology Chemical Pharmaceutical Customer Partnership Meeting Sep. 17, 2020, 9:00 AM - 5:00 PM ET [written description for antibodies; 101 & pharma patents; patent sequence searching, etc.]

  • 14 Sep 2020 4:37 PM
    Message # 9235154
    USPTO’s next Biotechnology, Chemical, and Pharmaceutical Customer Partnership (BCP) Meeting is scheduled for September 17, 2020 9:00 AM: 5:00 PM ET and will be held online.

    BCP meetings are part of a long-standing partnership between the USPTO and its valued stakeholders that works to improve the quality the agency’s products and services.

    The BCP Agenda is available for your review.

    The selected items from the Agenda is listed below:

    Time

    Title

    Presenter(s)

    9:10–9:50 a.m.

    Antibodies and the written description requirement of 35 U.S.C. 112(a)

    Daniel Kolker SPE, TC1600, USPTO [See Note 1]

    9:5010:20 a.m

    Written description for antibodies and other biologics

    Carla Mouta-Bellum, Ph.D., J.D. Partner, Arrigo, Lee, Guttman & Mouta-Bellum

    1:00 –2:30 p.m.

    Revised patent subject matter eligibility guidance

    Zachariah Lucas QAS, TC1600, USPTO

    2:30 –3:20 p.m.

    The impact of 101 on pharmaceutical patents

    MaCharri R. Vorndran-Jones, J.D.
    Assistant General Patent Counsel
    James P. Leeds, J.D. Assistant General Patent Counsel
    Eli Lilly and Company

    4:204:50 p.m.

    Basic introduction to searching patent sequence data using BLAST

    Peter S. Cooper, Ph.D. Staff Scientist User services, National Center for Biotechnology Information, NLM/NIH

    4:204:50 p.m.

    LensPatseq: An open facility for biotech patent professionals

    Osmat A. Jefferson, Ph.D., Director, Lens Product Development, Cambia, Professor of Science, Technology, and Law, Queensland University of Technology

    Presentations may start later or earlier than scheduled depending on how long the previous talks on the agenda will be.

    To register, please email USPTOBCP1600@USPTO.GOV by Tuesday, September 15. Make sure to include the following information: 

    • Subject: BCP RSVP
    • Your name, title, and organization
    • Contact information (e-mail, phone, etc.)

    Webex link to join

    https://www.uspto.gov/about-us/events/attend-biotechnology-chemical-and-pharmaceutical-partnership-meeting-0

     

    Note 1. Documents and presentations related written description of antibodies:

    USPTO Memorandum “Clarification of Written Description Guidance For Claims Drawn to Antibodies and Status of 2008 Training Materials", February 22, 2018, 2p.
    USPTO Antibody Decisions and Their Compliance with the Written Description Requirement. PowerPoint of the CBT [27 p, 2015]
    Feng, L., Lewis, S.D. (Finnegan) 2018. Patenting Antibodies: Written Description Concerns in Antibody Patents. IPWatchdog.com Blog. May 18, 2018.
    Yadav-Ranjan, K., 2020. Patenting Antibodies: A Complication in Written Description Jurisprudence. DePaul J. Health Care L. v. 21 No.3. Article 2 (24 p.)

    Update 9/14/2020: A title of Cambia talk has been changed by an author  to better reflect the content.

    Last modified: 16 Sep 2020 5:29 PM | Anonymous member

© 2020 The Patent Information Users Group, Inc.   

Mailing Address:  40 E. Main St., #1438

Newark, DE  19711

Phone: +1 (302) 660-3275   Fax: +1 (302) 660-3276

Email: PIUGinfo@piug.org

Webmaster: webmaster@piug.org

Follow PIUG:  

 

Go to PIUG wiki



Notice on use of PIUG name and logo:  

No one may use the PIUG name or logo for any promotional or commercial purpose or any other purpose without the prior written consent of the PIUG Board of Directors.  

Powered by Wild Apricot Membership Software